Eurazeo SE holds the cleaner structural position, with valuation as the main driver and stability adding further support. The remaining gap is narrow enough that the comparison remains open to different readings. In the market, Moderna carries the stronger setup — intact trend against Eurazeo SE's broken trend. That leaves a split case: the structural lead stays with Eurazeo SE, but the market is not currently confirming it.
The comparison is based on similar long-term financial trajectories, not sector labels. Peer scores are normalised within each company's primary universe (MRNA: S&P 500, RF.PA: STOXX 600).
The result is anchored in valuation, but stability also reinforces the same direction. Eurazeo SE leads by 8 points on the overall comparison score.
These two companies are linked by measured long-term financial trajectory similarity within the selected peer universe.
This level of similarity points to a meaningful structural match, though not a tight one.
The strongest overlap appears in margin trend and revenue growth trajectory.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The largest gaps do not all point in the same direction.
Left means cheaper relative valuation. Higher means stronger structure.
Moderna, Inc. holds the stronger structural profile, but the price setup still leans toward Eurazeo SE.
Valuation position uses peer-relative valuation score and Forward P/E where available.
Where MRNA and RF.PA each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
The main spread comes from a meaningfully cheaper peer-relative valuation.
On the market side, Moderna carries the stronger trend while Eurazeo SE's trend has broken — the market setup does not confirm the structural advantage.
Valuation is the clearest driver, and stability also supports Eurazeo SE's broader structural position.
Break down the MRNA vs RF.PA comparison across all dimensions with the full interactive tool.
Explore how MRNA and RF.PA each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.